Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch

Quest Diagnostics (DGX) drew fresh attention after announcing an Apple Health integration that allows iPhone and iPad users to order a preventive lab panel with more than 50 biomarkers for US$119. The Apple Health tie-in lands after a strong run in Quest Diagnostics’ shares, with the price up 15.6% over 90 days and 35.1% year to date, even though the last month’s share price return slipped 3.9% as traders reassessed shorter term risk and reward. Scan beyond Quest Diagnostics and see how other...